This bill amends the Uniform Controlled Substances Act in Nebraska by updating the schedules of controlled substances to better align with federal regulations and address emerging drug trends. It introduces new substances to Schedule I, including various fentanyl analogs and synthetic opioids, while deleting the entry for Brorphine. The bill also adds Mesocarb and Methiopropamine to Schedule II, and establishes a new category under Schedule III for Xylazine and its derivatives, with specific exemptions for veterinary use. Additionally, it clarifies definitions for hallucinogenic substances and modifies the classification of certain drugs, including the recognition of crystalline polymorph psilocybin as an FDA-approved pharmaceutical composition.

Furthermore, the bill enhances penalties for possession of money intended to facilitate violations of controlled substance laws, classifying such possession as a Class IV felony and allowing for asset forfeiture. It also outlines specific penalties for minors convicted of drug-related offenses, including educational and community service requirements. The bill includes various insertions and deletions to streamline legal language and improve clarity, ultimately aiming to strengthen the regulatory framework surrounding controlled substances in Nebraska while ensuring public safety.

Statutes affected:
Introduced: 28-405, 28-416